Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new 'French paradox'

Diabetes Metab. 2019 Sep;45(4):319-321. doi: 10.1016/j.diabet.2019.04.001. Epub 2019 Apr 18.

Authors

A J Scheen¹, P Darmon², H Hanaire³; writing committee of the position statement by the French-Speaking Society of Diabetes (SFD)

Affiliations

¹ Service de diabétologie, nutrition et maladies métaboliques, CHU de Liège, Liège université, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.
² Pôle endocrinologie, nutrition, diabète et obésité, hôpital de la Conception, Aix-Marseille université, Inserm, Inra, C2VN, 13005 Marseille, France.
³ Service de diabétologie, CHU Rangueil, 31400 Toulouse, France.

PMID: 31005757
DOI: 10.1016/j.diabet.2019.04.001

No abstract available

Keywords: SGLT2 inhibitors; ‘French paradox’.

Publication types

Editorial

MeSH terms

Alcohol Drinking / physiopathology*
Amputation, Surgical / economics
Amputation, Surgical / statistics & numerical data
Cardiotonic Agents / pharmacology
Cardiovascular Diseases / physiopathology
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / economics
Diabetes Mellitus, Type 2 / physiopathology
Diabetic Angiopathies / physiopathology
Diabetic Angiopathies / prevention & control
Diabetic Ketoacidosis / chemically induced
Diabetic Ketoacidosis / economics
Diabetic Ketoacidosis / epidemiology
Drug-Related Side Effects and Adverse Reactions / economics
Drug-Related Side Effects and Adverse Reactions / epidemiology
France
Health Care Costs
Humans
Medical Futility
Risk Assessment
Secondary Prevention / economics
Secondary Prevention / methods
Secondary Prevention / standards
Sodium-Glucose Transporter 2 Inhibitors / adverse effects
Sodium-Glucose Transporter 2 Inhibitors / economics
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome
Wine*

Substances

Cardiotonic Agents
Sodium-Glucose Transporter 2 Inhibitors